ClinicalTrials.gg
RecruitingNCT06787482RetinoUpdated Apr 25, 2025

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

A Phase 1/2 interventional study of ACE Retino in Retinitis Pigmentosa (RP), Age Related Macular Degeneration and Diabetic Retinopathy, sponsored by Ace Cells Lab Limited. Recruiting at 2 sites in Egypt. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by Ace Cells Lab Limited · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Sex
All
01

Study summary

Summary of the Study This clinical trial evaluates a novel peptide-based therapy for treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR). The therapy consists of peptides derived from fetal tissues, mesenchymal stem cells (MSCs), and bioactive growth factors, administered sublingually for systemic absorption.

Study Objectives:

Primary Objectives: Assess safety and tolerability, and evaluate the therapy's effects on retinal function and structure.

Secondary Objectives: Explore improvements in visual acuity, retinal thickness, vascular health, and disease biomarkers.

Study Design:

Type: Open-label, single-arm interventional study. Duration: 12 months.

Participants: 150 adults, divided into three cohorts:

Retinal dystrophies. AMD (dry and wet forms). DR (moderate NPDR and PDR).

Intervention:

A sublingual solution containing peptides and growth factors, taken 4 times daily.

Outcome Measures:

Primary Outcomes: Safety (adverse events) and tolerability (treatment adherence).

Secondary Outcomes:

Functional: Visual acuity and field sensitivity improvements. Structural: Retinal thickness and vascular health. Biomarkers: Serum VEGF, oxidative stress, and inflammatory markers.

Study Procedures:

Monthly follow-ups for safety monitoring, vision tests, retinal imaging (OCT, FA), and blood biomarker analysis.

Comprehensive evaluations at baseline, 6 months, and 12 months. Significance: The study aims to provide an innovative, non-invasive treatment for debilitating retinal conditions, potentially improving vision and retinal health through systemic therapy.

Read the detailed description

Protocol for Evaluating a Novel Peptide-Based Therapy in Retinal Dystrophies, Age-Related Macular Degeneration, and Diabetic Retinopathy

Authors :

Mohamed Yasser Sayed Saif Prof of ophthalmology , Beni-Suef University Sherin Amer Family medicine consultant, Alaa Abdelkarim Endocrinology consultant , ACE Cells Lab Ahmed Tamer Sayed Saif Assistant Professor of ophthalmology, Fayoum University Passant Sayed Saif Assistant Professor of Ophthalmology, Misr University for Science and Technology

  1. Background and Rationale Retinal diseases such as retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR) are among the leading causes of blindness worldwide. These conditions result from different pathophysiological mechanisms but share common features like oxidative stress, chronic inflammation, and cellular degeneration.

    The novel therapy under evaluation consists of low molecular weight peptides derived from fetal tissues and mesenchymal stem cells (MSCs). The formulation also incorporates bioactive growth factors and essential peptides to support retinal health and regeneration. Sublingual administration ensures systemic absorption and avoids invasive delivery methods.

  2. Objectives

<!-- -->

  1. Primary Objectives

    • Assess the safety and tolerability of the peptide-based therapy.
    • Evaluate its effects on retinal function and structure in patients with retinal dystrophies, AMD, and DR.
  2. Secondary Objectives

    • Explore improvements in visual function (acuity, field sensitivity).
    • Monitor changes in retinal thickness and vascular health.
    • Investigate its impact on disease biomarkers in the blood (e.g., VEGF, oxidative stress markers).
  3. Study Design • Type: Open-label, interventional, single-arm study.

    • Duration: 12 months.
    • Participants: 150 participants, stratified equally into three cohorts:

      • Cohort 1: Retinal dystrophies (e.g., macular dystrophy, Stargardt disease).
      • Cohort 2: AMD (both dry and wet forms).
      • Cohort 3: Diabetic retinopathy (moderate NPDR and PDR).
  4. Participants 4.1 Inclusion Criteria

    • Adults aged 18-80 years diagnosed with retinal dystrophies, AMD, or DR.
    • BCVA between 20/40 and 20/400 in the study eye.
    • Evidence of disease progression within the last 12 months (e.g., worsening visual acuity, OCT changes).
    • Stable systemic conditions allowing safe participation. 4.2 Exclusion Criteria
    • Active ocular infections or inflammation.
    • Recent ocular surgeries (within 3 months).
    • Co-existing advanced glaucoma or other retinal diseases.
    • Pregnancy or breastfeeding.
    • Hypersensitivity to components of the peptide formulation.
  5. Intervention 5.1 Study Drug

    • Formulation: Sublingual solution containing peptides derived from fetal retinal, optic nerve, and neural tissues, MSC-derived peptides, and platelet growth factors.
    • Dosage: 1.0 mL sublingually, four times daily. 5.2 Administration
    • Self-administered by participants in the morning and evening.
  6. Outcome Measures 6.1 Primary Outcomes • Safety:

    • Incidence and severity of adverse events (AEs) over 12 months. • Tolerability:
    • Adherence to treatment regimen and participant-reported discomfort. 6.2 Secondary Outcomes

<!-- -->

  1. Functional Outcomes:

    o BCVA changes measured using ETDRS charts.

    • Visual field sensitivity improvement assessed by automated perimetry.
  2. Structural Outcomes:

    o Retinal thickness and photoreceptor integrity evaluated by SD-OCT.

    o Vascular leakage and neovascularization assessed using fluorescein angiography (FA) and OCT angiography (OCTA).

  3. Biochemical and Biomarker Outcomes:

    • Serum VEGF levels and oxidative stress markers.
    • Inflammatory cytokine profiles (e.g., IL-6, TNF-α).
  1. Study Procedures 7.1 Screening Visit
  1. Informed Consent: Participants will provide written consent after a detailed explanation of the study.
  1. Baseline Assessments:
  • Comprehensive medical and ocular history.
  • BCVA measurement using ETDRS charts.
  • SD-OCT imaging of retinal structure.
  • FA and OCTA for vascular assessment.
  • Blood sampling for biomarkers (VEGF, inflammatory cytokines). 7.2 Monthly Follow-Up Visits 1. Safety Monitoring: Documentation of AEs and systemic health assessment. 2. Ocular Assessments:
  • BCVA measurement.
  • SD-OCT imaging to monitor retinal thickness and integrity.
  • OCTA and FA for vascular changes (if indicated). 7.3 Midpoint Visit (6 Months) 1. Repeat all baseline assessments, including biomarkers and electrophysiology (full-field ERG).

7.4 End-of-Study Visit (12 Months)

  1. Comprehensive evaluation of functional, structural, and biochemical outcomes.
  2. Participant feedback on therapy tolerability and perceived benefits.
  1. Statistical Analysis
  1. Sample Size Justification:

o Effect size and variability for BCVA improvement and retinal thickness changes are estimated from previous studies. A sample size of 150 ensures 80% power to detect a clinically meaningful difference at a 5% significance level.

  1. Data Analysis Plan:
  • Continuous variables (e.g., BCVA, OCT metrics) analyzed using paired t-tests or ANOVA.
  • Proportions of responders (e.g., those with BCVA improvement ≥5 letters) analyzed using chi-square tests.
  • Correlation analysis between biomarkers and functional outcomes.

    1. Ethical Considerations
    2. Regulatory Compliance:
  • Conducted per the Declaration of Helsinki and ICH-GCP guidelines. 2. IRB Approval: Secured before study commencement. 3. Informed Consent: Participants provided detailed study information and signed consent forms.

    1. Data Confidentiality: All participant data anonymized and securely stored.
    1. References
    2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection. Lancet Glob Health. 2014;2

      . doi:10.1016/S2214-109X(13)70145-1.

    3. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-36. doi:10.1016/S0140-6736(09)62124-3.
    4. Scholl HP, Strauss RW, Singh MS, et al. Emerging therapies for inherited retinal degeneration. Sci Transl Med. 2016;8:368rv6. doi:10.1126/scitranslmed.aaf2838.
    5. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653-64. doi:10.2337/diacare.26.9.2653.
02

Conditions studied

  • Retinitis Pigmentosa (RP)
  • Age Related Macular Degeneration
  • Diabetic Retinopathy
03

In context

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

This study's planned enrollment of 100 is above the median of 27 across 180 interventional studies indexed under Retinitis Pigmentosa.

Browse Retinitis Pigmentosa studies →

Lead sponsor

Ace Cells Lab Limited is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Adults aged 18-65 years with a confirmed genetic or clinical diagnosis of RP.

      • Visual acuity of ≥1/60 in at least one eye.
      • Stable ocular and systemic condition over the past six months.
      • Ability to provide written

Exclusion criteria

Exclusion Criteria:

    • Significant ocular comorbidities (e.g., advanced glaucoma, diabetic retinopathy).

      • Recent ocular surgery (within six months) or current use of drugs.
      • Systemic conditions affecting study outcomes (e.g., uncontrolled diabetes, diseases).
      • Pregnancy or lactation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    administer 1 ml of Ace Retino 4 times daily for 6 months,safety evaluation

    Primary Objective: Evaluate the safety and tolerability of ACE Retino in individuals with RP.

    Dietary Supplement: ACE Retino

  • Experimental
    test efficacy for ACE Retino 1 ml 4times daily sublingual for 6 months

    Assess the efficacy of ACE Retino in improving retinal structure and function. Explore the potential for photoreceptor and retinal pigment epithelial (RPE) regeneration.

    Dietary Supplement: ACE Retino

Interventions

  • Dietary supplementACE Retino

    1 ml sublingually self administer / 4 times/day for 6 months

06

What researchers measure

Primary outcomes

  1. change in BVCA

    change in BCVA (best-corrected visual acuity). The calculation is based on detecting a clinically meaningful improvement in BCVA using a paired design (before and after treatment within the same subjects).

    Time frame: 3 months

Secondary outcomes

  1. change in OCT

    change in OCT curves and numbers based on before and after results

    Time frame: 3 months

07

Study locations

2 of 2 sites recruiting
  • Dr. Seif Clinic
    Cairo, Egypt
    Recruiting
    • Dr. Mohammed Yasser Sayed Saif, PhD Ophthalmology, professor · Contactdralaakarim@gmail.com · +20 100 669 9288
    • Dr. Mohammed Yasser Sayed Saif, PhD Ophthalmology, professor · Principal investigator
    • Dr. Bassant Sayed Saif, PhD Ophthalmology, Ass. Prof. · Principal investigator
    • Dr. Ahmed Tamer Syed Saif, Ass. Prof. Ophthalmology · Principal investigator
  • British Center for Regeerative medicne (Cairo)
    Giza, !2112, Egypt
    Recruiting
    • Dr. Alaa Abdelkarim Mohammed, MRCPUK Endocrinology · Contactdralaakarim@gmail.com · +201110787773
    • Dr. Shireen Amer, M.Sc Occupational&industrial M · ContactShireenamer@gmail.com · +20 100 069 9555
    • Dr. Alaa Abdelkarim Mohammed, MRCPUK Endocrinology · Sub investigator
    • Dr. Shireen Aner, Master Family Medicine · Sub investigator
    • Dr. Yasser Seif, PhD Ophthalmology · Principal investigator
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2025, 7 months after the start.

Of 29 phase 1/2 interventional studies under Retinitis Pigmentosa, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 92. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 22, 2025
StartActual
Nov 12, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Dec 2025
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06787482
Lead sponsor
Ace Cells Lab Limited
Collaborators
European Wellness Academy
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
Nov 12, 2024
Primary completion
Jun 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 25, 2025

Study contacts

Dr. Alaa Abdelkairm Mohammed, MRCPUK Endocrinology
Contact
dralaakarim@gmail.com
+447473922553
Dr. Shireen Amer, M.Sc Occupational&industrial M
Contact
Shireenamer@gmail.com
+20 100 069 9555
Dr. Passant Sayed Saif, PhD ophthalmology
principal investigator · Associate prof of Ophthalmology Misr University for science and technology
Dr. Mohammed Yasser Sayed Saif, PhD Ophthalmology
principal investigator · Dean of NILES Prof of Ophthalmology Beni-Suef University
Dr. Alaa Abdelkarim Mohammed, MRCPUK Endocirnology
principal investigator · ACE Cells Lab Limited Chief Medical Consultant
Dr. Ahmed Tamer Sayed Saif, PhD Ophthalmology
principal investigator · Chairman of Ophthalmology department Associate prof of Ophthalmology Fayoum university
DR. Mike Chan, stem cells expert
study chair · European Wellness Academy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion